Market dynamics — growth × size (bubble, multi-level drill)
x=growth · y=value(log) · bubble=value · blue ring=Amarox. Pick the level, then click any bubble to drill. Sector & company-type filters apply.
🔼 Fastest-growing classes
🔽 Declining classes
⚔️ Most contested (open — weak leader)
🏰 Most locked (dominant leader)
Head-to-Head Lab
Compare side by side. Companies (colour = type), Brands (DIRECT if same ATC4 else INDIRECT), or Molecules. Sector & company-type filters apply to the pick list.
Amarox lens — PRISM policy
Amarox as one player. PRISM is the decision classification. Sector filter recomputes value & share.
PRISM tier mix
PRISM% vs share
Amarox action map — where to grow, defend, convert & enter
Amarox's own brands classified for action (PRISM + Evolution Index), plus open whitespace. Respects the Sector, Scope & ATC1 filters. Click any row to open the brand or focus the class.
🚀 Grow — top reachable SAR
🛡 Defend — highest value-at-risk
💰 Convert — strong PRISM, low share
🎯 Enter — whitespace (open & growing)
Amarox Portfolio Dashboard — every brand vs its ATC4 market
House brand-equity format. Each Amarox brand with its relative ATC4 market: players, total market, leader, BE value/units, rank, MS%, brand-equity (vs leader=100%), growth, PRISM. Click a row to open the class & the brands inside it. Sector & value/unit aware.
Column guide (key):
Contribution % = the brand's OWN share of total Amarox sales = brand value ÷ total Amarox sales. e.g. Cardiva 59.4M ÷ 275.2M = 21.6% · MELIGAMET 21.7M = 7.9% · Pressura 9.9M = 3.6%. This is the contribution of each product.
Cumul % = the running total of Contribution % added down the sorted list (biggest first). It is NOT a single brand's contribution: e.g. Pressura's Cumul 54% = Cardiva+…+Pressura combined, while Pressura's own contribution is 3.6%. Why it matters (concentration / dependency risk): the row where Cumul passes 80% is your "vital few" (here 17 of 68 brands) — 80% of Amarox revenue rides on ~25% of the portfolio. Brands above the 80% line = the core to protect & grow; brands in the bottom 5% = the long tail to prune / bundle / streamline. Rising over time = more dependent on fewer brands (riskier); falling = diversifying.
MS% = brand ÷ total ATC4 market · Brand-equity = brand ÷ class leader (leader = 100%) · Mkt GR = the whole class's YoY growth · Brand GR = the Amarox brand's own YoY growth (— = no prior-year base) · EI = brand growth ÷ class growth ×100 (>100 gaining share).
Contribution % = the brand's OWN share of total Amarox sales = brand value ÷ total Amarox sales. e.g. Cardiva 59.4M ÷ 275.2M = 21.6% · MELIGAMET 21.7M = 7.9% · Pressura 9.9M = 3.6%. This is the contribution of each product.
Cumul % = the running total of Contribution % added down the sorted list (biggest first). It is NOT a single brand's contribution: e.g. Pressura's Cumul 54% = Cardiva+…+Pressura combined, while Pressura's own contribution is 3.6%. Why it matters (concentration / dependency risk): the row where Cumul passes 80% is your "vital few" (here 17 of 68 brands) — 80% of Amarox revenue rides on ~25% of the portfolio. Brands above the 80% line = the core to protect & grow; brands in the bottom 5% = the long tail to prune / bundle / streamline. Rising over time = more dependent on fewer brands (riskier); falling = diversifying.
MS% = brand ÷ total ATC4 market · Brand-equity = brand ÷ class leader (leader = 100%) · Mkt GR = the whole class's YoY growth · Brand GR = the Amarox brand's own YoY growth (— = no prior-year base) · EI = brand growth ÷ class growth ×100 (>100 gaining share).
Opportunity Radar — Whitespace (where Amarox is NOT present yet)
Pure entry-opportunity view, separate from the Portfolio Dashboard (which covers your current brands). These are attractive ATC4 classes where Amarox has no brand — ranked by an open Opportunity score = market size × growth × openness (lower HHI = more open). All figures are the current Market Audit YTD · May 2026. PRISM stays the product classification; this adds market-structure context only. Sector & scope aware.
◎ Whitespace opportunity map — growth × market size (bubble = market openness)
Only classes with no Amarox brand are plotted. Up-and-right = big & fast-growing = most attractive to enter. Bigger bubble = more fragmented (lower barrier). Colour = incumbent leader's PRISM strength (greener = weaker leader = easier). Click a bubble to open the class & its leader.
▣ Whitespace — entry targets (ranked)
Key: Opportunity score = (market size, SAR M) × (1 + class growth) × openness (fragmented ×1.3 · moderate ×1.0 · concentrated ×0.7) — a transparent ranking, all raw inputs shown. HHI = class concentration (lower = more fragmented = easier to take share). Leader PRISM = how strong the incumbent #1 is (a MEGA leader is harder to displace). Click any row to open the class & its leader. Discovery aid — validate clinical fit, registration status & supply before committing. For your CURRENT brands & their growth headroom, use the Portfolio Dashboard.
KSA Market Explorer — the whole pharma landscape
The total KSA market by therapy area (ATC1), current Market Audit YTD · May 2026. Value & share are YTD; growth is YoY (single-period, honestly labelled — not a multi-year CAGR). Click a bar to drill into that ATC1 in the Funnel. Where Amarox plays is highlighted.
Therapy areas (ATC1) by value · YTD
Market share split (ATC1)
360 View — Companies in the KSA pharma league & Amarox's place in it
Top companies in KSA by value (YTD May-2026), with brand count and PRISM-weighted portfolio strength. Colour = company type. Responds to Sector, Scope & Company-Type filters — values aggregated live from brand-level data (≈95% coverage of the audited company total; Amarox exact). Click any company (bar, bubble or row) to open its full portfolio.
Top-20 companies by value · YTD
Portfolio map — brands × value (bubble = PRISM strength)
Strategic groups — price × depth (bubble = sales)
Profit-pool map — therapy areas (bubble = market value)
Brands = how many products a company sells (breadth/size). PRISM strength = value-weighted average product PRISM (portfolio quality 0–100 — how strong each brand is, weighted by sales). Stars = BCG stars · #1 = class leaders. Click any column header to re-sort. Click any company (bar, bubble or row) to open its full portfolio.
Competitive read — breadth × quality, opportunities & threats
Reads the table above for Amarox: who is broad-but-weak (attack), who is focused-and-strong (defend), and the direct threats inside Amarox's own classes. Respects the Sector, Scope & Company-Type filters.
🎯 Opportunities — attack targets (broad & weak, in our classes)
⚠️ Threats — strong rivals inside our classes
Company H2H — compare any pharma companies side by side
Pick 2–6 companies (Amarox ◆ is the anchor). Compare value, brand count, PRISM-weighted portfolio strength, leaders and channel mix — Sector & Scope aware, YTD May-2026. Click a company to open its full portfolio. No multi-year CAGR (not in the data) — only metrics the data supports.
Add any company:◆ Amarox · ▣ national · ▢ multinational/intl
Value (bars) & PRISM strength (line)
Channel mix (Retail / Hospital / Others)
Value = sector/scope-aware, aggregated from brand-level data (≈95% coverage; Amarox exact). PRISM strength = value-weighted avg product PRISM (0–100). Channel mix = each company's Retail/Hospital/Others split.
PM 360 — Product Manager assessment workbench
A single 360° view per Amarox product for the marketing team: performance vs last year & vs the market, PRISM evaluation with the path to the next tier and future potential, direct & indirect competition, share-shift & risk, stress-test scenarios, missed opportunities, data uncertainties, and the required marketing actions to improve or correct — all in one place. Sector/Scope aware · Market Audit YTD May-2026.
Product Manager Product